Highlights Newsletter 2 This newsletter presents you the following key sessions: Watch the video interview with professor B. Neyns about the long-term follow-up data of a large randomised EORTC trial with adjuvant ipilimumab versus placebo in patients with metastatic melanoma No overall survival benefit with custirsen in metastatic prostate cancer Cabozantinib delays disease progression compared to sunitinib in metastatic renal cell carcinoma patients with a poor prognosis First-line treatment with pembrolizumab in combination with chemotherapy improves the outcomes in advanced NSCLC Neoadjuvant chemotherapy with an anthracycline and ifosfamide is better than histology-driven chemotherapy in patients with high-risk soft tissue sarcoma